During the past decade, Fakultni nemocnice Ostrava, Klinika hematoonkologie conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" #1 sponsor was "Genentech, Inc." with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Rigel Pharmaceuticals" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" are "Multiple Myeloma" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Warm Antibody Autoimmune Hemolytic Anemia" (2 trials), "Chronic Myelomonocytic Leukemia" (1 trials) and "Leukemia, Myeloid, Acute" (1 trials). Many other conditions were trialed in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" in a lesser frequency.

Most popular intervention types in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" are "Drug" (11 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Azacitidine" (2 trials), "Dexamethasone" (2 trials), "Fostamatinib disodium" (2 trials) and "Pomalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fakultni nemocnice Ostrava, Klinika hematoonkologie" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Fakultni nemocnice Ostrava, Klinika hematoonkologie". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in Fakultni nemocnice Ostrava, Klinika hematoonkologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fakultni nemocnice Ostrava, Klinika hematoonkologie, 3 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".